We are live on ! Find out more
BIOC

Biocept, Inc.

Delisted

BIOC was delisted on the 24th of October, 2023.

26 hedge funds and large institutions have $1.57M invested in Biocept, Inc. in 2022 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, 7 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

2,650% more call options, than puts

Call options by funds: $110K | Put options by funds: $4K

4% less funds holding

Funds holding: 2726 (-1)

12% less capital invested

Capital invested by funds: $1.78M → $1.57M (-$209K)

25% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 4

86% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 7

Holders
26
Holders Change
-1
Holders Change %
-3.7%
% of All Funds
0.45%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
3
Increased
1
Reduced
7
Closed
4
Calls
$110K
Puts
$4K
Net Calls
+$106K
Net Calls Change
-$70K
Name Holding Trade Value Shares
Change
Change in
Stake
VF
26
Virtu Financial
New York
-$27K -940 Closed
Jane Street
27
Jane Street
New York
-$13K -469 Closed
SWM
28
Spire Wealth Management
Virginia
-$4K -133 Closed

BIOC Hedge Fund Activity: Q3 2022 in Review

26 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in Biocept, Inc. (BIOC) for Q3 2022, worth a combined $1.57M — down 12% from $1.78M a quarter earlier.

Sellers outnumbered buyers: 4 funds closed out of BIOC and 3 opened new positions — a net loss of 1 holder — while 7 trimmed existing stakes and 1 added.

The largest buyer was Susquehanna International Group, opening a new position worth an estimated $19.4K. The largest seller was Millennium Management, cutting an estimated $65.2K.

  • 26 institutional investors held Biocept, Inc. (BIOC) as of Q3 2022, down from 27 in Q2 2022.
  • Funds reported $1.57M of Biocept, Inc. stock for Q3 2022, down 12% quarter-over-quarter.
  • 3 funds opened new Biocept, Inc. positions in Q3 2022 and 4 closed out, a net change of -1 holder.
  • The largest Biocept, Inc. buyer in Q3 2022 was Susquehanna International Group, an estimated $19.4K added.
  • The largest Biocept, Inc. seller in Q3 2022 was Millennium Management, an estimated $65.2K sold.

Based on aggregated 13F filings for Q3 2022.